Drospirenone/Ethinyl Estradiol Versus Rosiglitazone Treatment in Overweight Adolescents with Polycystic Ovary Syndrome: Comparison of Metabolic, Hormonal, and Cardiovascular Risk Factors

CONTEXT: Adolescents with polycystic ovary syndrome (PCOS) have insulin resistance and higher rates of the metabolic syndrome. OBJECTIVE: Our objective was to compare the effects of 6 months treatment with drospirenone/ethinyl estradiol (EE) (3 mg/30 μg) vs. rosiglitazone (4 mg) daily on the hormona...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Tfayli, Hala, Ulnach, Julia Warren, Lee, SoJung, Sutton-Tyrrell, Kim, Arslanian, Silva
Natura: Artigo
Lingua:Inglês
Pubblicazione: Endocrine Society 2011
Soggetti:
Endocrine Care
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3203622/
https://ncbi.nlm.nih.gov/pubmed/21325466
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2010-2547
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi